Dr. Annaliesa S. Anderson is Senior Vice President and Chief Vaccines Officer at Pfizer. With over 30 years in pharmaceuticals, she leads global vaccine research, development, and medical affairs, advancing programs from early discovery through post-licensure—including candidates for C. difficile, Lyme disease, Group B Strep, and more. Dr. Anderson earned her PhD in biological sciences from the University of Warwick and has contributed to the development of numerous licensed vaccines, including for HPV at Merck and for pneumococcal disease, meningococcal disease, COVID-19, and RSV at Pfizer. During the SARS-CoV-2 pandemic, she co-led the development of an antiviral therapy for COVID-19. Dr. Anderson has co-authored over 170 peer-reviewed publications and book chapters and holds an extensive patent portfolio. In 2024, she was named among the Top 20 Women in Biopharma by Endpoints. She is a Fellow of the American Academy of Microbiology, the Infectious Diseases Society of America, the Academy of Medical Sciences, and the Royal Society of Medicine, and serves on multiple scientific and policy advisory boards.